Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
North Carolina macular dystrophy (NCMD) is a non-progressive autosomal dominant macular disorder of congenital or infantile onset characterized by loss of central vision, the accumulation of drusen in the macula and atrophy of photoreceptor cells with a variable phenotype at macular examination.
Features include always present findings: Reduced visual acuity and Macular dystrophy. 7 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Peripheral retinal atrophy, Abnormality of macular pigmentation, Macular dystrophy |
Biomarker and diagnostic research for North Carolina macular dystrophy has been reported in the published literature.
Phenotype severity distribution: 2 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for North Carolina macular dystrophy.
26 publications have been identified in PubMed for North Carolina macular dystrophy. Research spans Basic Science / Preclinical (31%), Review / Meta-Analysis (19%), and Other (12%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 8 | 31% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 11:06 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about North Carolina macular dystrophy
1 |
Peripheral retinal atrophy |
5 |
19% |
Other research | 3 | 12% |
New treatment approaches | 3 | 12% |
Patient case studies | 2 | 8% |
Clinical study results | 2 | 8% |
Disease patterns and progression | 2 | 8% |
Testing and diagnosis research | 1 | 4% |
Rotstein DL (2026). [PMID: 41722595](https://pubmed.ncbi.nlm.nih.gov/41722595/). *The Lancet. Neurology*. [Basic Science / Preclinical]
Quinodoz M (2026). [PMID: 41513982](https://pubmed.ncbi.nlm.nih.gov/41513982/). *Nature genetics*. [Basic Science / Preclinical]
Spedicati B (2025). [PMID: 40868158](https://pubmed.ncbi.nlm.nih.gov/40868158/). *Biomedicines*. [Gene Therapy / Novel Therapeutics]
Diaz A (2025). [PMID: 40736823](https://pubmed.ncbi.nlm.nih.gov/40736823/). *Advances in experimental medicine and biology*. [Other]
Bommakanti N (2025). [PMID: 39401482](https://pubmed.ncbi.nlm.nih.gov/39401482/). *Retinal cases & brief reports*. [Case Report / Case Series]
Pederzolli M (2025). [PMID: 40400237](https://pubmed.ncbi.nlm.nih.gov/40400237/). *Ophthalmic genetics*. [Case Report / Case Series]
Berk JL (2025). [PMID: 40555140](https://pubmed.ncbi.nlm.nih.gov/40555140/). *JACC. Advances*. [Clinical Trial Publication]
Wang X (2025). [PMID: 39732214](https://pubmed.ncbi.nlm.nih.gov/39732214/). *International journal of pharmaceutics*. [Basic Science / Preclinical]
Moekotte L (2025). [PMID: 39982393](https://pubmed.ncbi.nlm.nih.gov/39982393/). *Investigative ophthalmology & visual science*. [Basic Science / Preclinical]
Charbel Issa P (2025). [PMID: 39820891](https://pubmed.ncbi.nlm.nih.gov/39820891/). *Klinische Monatsblatter fur Augenheilkunde*. [Other]